Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Obesity Management and Cardiovascular Disease
Author(s): Miao Gao , Tanjot Singh , Ramzi Ajjan Added: 1 month ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Preterm Birth and Maternal Cardiovascular Risk
Author(s): Jorge Segovia-Reyes , Andrea Iboleon-Jimenez , María Jiménez-Salva , et al Added: 5 days ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Between the Sessions with Dr Parwani: VESALIUS-CV, KARDINAL, CHIP-BCIS3 & M
Author(s): Purvi Parwani Added: 1 month ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more

Intervention

Prevention & Chronic Conditions
Frailty and Cardiovascular Risk
Author(s): Nicholas R Evans , Shiv Bhakta , Claudia Zeicu , et al Added: 1 week ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Maria Fernández García , Alberto Alen Andrés , Beatriz Nieves Ureña , et al Added: 3 weeks ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s): Roberta Esposito , Pierantonio Menna , Emanuela Salvatorelli , et al Added: 7 months ago

CV Disease in Special Populations

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Laura Pérez Bacigalupe , Laura López Ruiz , Beatriz Nieves Ureña , et al Added: 3 weeks ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ACC 26: AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
Author(s): Michael McConnell Added: 1 month ago
ACC.26 – Dr Michael McConnell (Stanford Health Care, Stanford, CA, US) joins us to discuss findings from a prospective, multicentre clinical trial evaluating whether artificial intelligence analysis of retinal images can identify patients at elevated atherosclerotic cardiovascular risk.Findings showed strong sensitivity and specificity in identifying those at risk of ASCVD in a diverse study… View more

Prevention & Chronic Conditions

Digital Health